Phase I study of BC001, a novel fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2, in advanced solid tumors.

MLA

Liu, Dan, et al. “Phase I Study of BC001, a Novel Fully Human Immunoglobulin G1 Monoclonal Antibody Targeting the Vascular Endothelial Growth Factor Receptor-2, in Advanced Solid Tumors.” Cancer Medicine, vol. 13, no. 22, Nov. 2024, p. e70208. EBSCOhost, https://doi.org/10.1002/cam4.70208.

APA

Liu, D., Gong, J., Liu, M., Zhou, H., Wang, S., Yang, J., Shang, C., Guo, X., Wang, C., Zhang, Y., & Shen, L. (2024). Phase I study of BC001, a novel fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2, in advanced solid tumors. Cancer Medicine, 13(22), e70208. https://doi.org/10.1002/cam4.70208

Chicago

Liu, Dan, Jifang Gong, Muling Liu, Huan Zhou, Shumei Wang, Jian Yang, Chenwei Shang, et al. 2024. “Phase I Study of BC001, a Novel Fully Human Immunoglobulin G1 Monoclonal Antibody Targeting the Vascular Endothelial Growth Factor Receptor-2, in Advanced Solid Tumors.” Cancer Medicine 13 (22): e70208. doi:10.1002/cam4.70208.